TREACE MEDICAL CONCEPTS INC (TMCI) Stock Price, Forecast & Analysis
USA - NASDAQ:TMCI - US89455T1097 - Common Stock
TMCI Key Statistics, Chart & Performance
The current stock price of TMCI is 6.23 USD. In the past month the price increased by 3.32%. In the past year, price decreased by -22.51%.
TMCI Latest News, Press Relases and Analysis
TMCI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.04 | 217.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.62 | 196.37B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.58 | 146.77B | ||
| SYK | STRYKER CORP | 26.86 | 135.27B | ||
| MDT | MEDTRONIC PLC | 16.29 | 115.52B | ||
| IDXX | IDEXX LABORATORIES INC | 56.6 | 57.10B | ||
| BDX | BECTON DICKINSON AND CO | 12.43 | 50.85B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.40B | ||
| RMD | RESMED INC | 25.22 | 36.43B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.16 | 33.86B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.01 | 27.19B | ||
| STE | STERIS PLC | 26.35 | 25.61B |
Related stock screener links
About TMCI
Company Profile
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
Company Info
TREACE MEDICAL CONCEPTS INC
100 Palmetto Park Place
Ponte Vedra FLORIDA 32081 US
CEO: John T. Treace
Employees: 477
Phone: 19043735940
TREACE MEDICAL CONCEPTS INC / TMCI FAQ
Can you describe the business of TREACE MEDICAL CONCEPTS INC?
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
Can you provide the latest stock price for TREACE MEDICAL CONCEPTS INC?
The current stock price of TMCI is 6.23 USD. The price decreased by -0.32% in the last trading session.
Does TMCI stock pay dividends?
TMCI does not pay a dividend.
What is the ChartMill technical and fundamental rating of TMCI stock?
TMCI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists TMCI stock?
TMCI stock is listed on the Nasdaq exchange.
Should I buy TMCI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TMCI.
Is TREACE MEDICAL CONCEPTS INC (TMCI) expected to grow?
The Revenue of TREACE MEDICAL CONCEPTS INC (TMCI) is expected to grow by 9.29% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
TMCI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TMCI. When comparing the yearly performance of all stocks, TMCI is a bad performer in the overall market: 77.86% of all stocks are doing better.
TMCI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TMCI. Both the profitability and financial health of TMCI have multiple concerns.
TMCI Financial Highlights
Over the last trailing twelve months TMCI reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 18.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.82% | ||
| ROE | -50.38% | ||
| Debt/Equity | 0.56 |
TMCI Forecast & Estimates
12 analysts have analysed TMCI and the average price target is 8.67 USD. This implies a price increase of 39.17% is expected in the next year compared to the current price of 6.23.
For the next year, analysts expect an EPS growth of 3.2% and a revenue growth 9.29% for TMCI